Antiretroviral drug resistance in HIV-infected children: Implications for long-term treatment

Journal of HIV Therapy

Volumn 12, Issue 4, 2007, Pages 99-100

  Tudor Williams, Gareth ^a   Green, Hannah ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LOPINAVIR PLUS RITONAVIR; NELFINAVIR;

ANTIVIRAL THERAPY; CONFERENCE PAPER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; VIRUS INFECTION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; CHILD; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS;

EID: 40649116018     PISSN: 14620308     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (7)

1. Gibb DM, Duong T, Tookey PA et al.; on behalf of the National Study of HIV in Pregnancy and Childhood (NSHPC) and the Collaborative HIV Paediatric Study (CHIPS). Decline in mortality, AIDS and hospital admissions in perinatally HIV-1 infected children in the UK and Ireland. BMJ, 2003, 327, 1019.
2. Gibb DM, Melvin A, Compagnucci A et al.; on behalf of the PENPACT 1 Trial. Choice of first-line ART regimen in PENPACT 1: a randomized trial of combination antiretroviral regimens and treatment switching strategies in antiretroviral naive children > 30 days and <18 years of age. XV International AIDS Conference, 11-16 July 2004, Bangkok. Poster TuPeB4442.
3. The PENTA 5 Writing Committee. A randomised trial to compare dual nucleoside-analogue reverse transcriptase inhibitor regimens (ZDV+3TC or ZDV+ABC or 3TC+ABC) with and without a protease inhibitor (nelfinavir) in previously untreated HIV-infected children: the PENTA 5 trial. Lancet, 2002, 359, 733-740.
4. Gibb DM, Green H, Saidi Y et al.; on behalf of PENTA 5. 3TC+ABC maintains virological superiority over ZDV+3TC and ZDV+ABC beyond 5 years in children: the PENTA 5 trial. AIDS, 2007, 21, 947-955.
5. Lee KJ, Lyall H, Walker AS et al. Wide disparity in switch to second-line therapy in HIV infected children in CHIPS. 8th International Congress on Drug Therapy in HIV infection, Glasgow, 2006. Oral paper PL 2.4.
6. Chakraborty R, Smith CJ, Dunn D et al. HIV-1 drug resistance in HIV-1 infected children in the United Kingdom from 1998 to 2004. Paediatr Infect Dis J, in press.
7. Aboulker J-P, Babiker A, Bacheler L et al.; on behalf of the PENTA 8 study group. A randomised controlled trial of genotypic HIV drug resistance testing in HIV-1 infected children: the PERA (PENTA 8) trial. Antivir Ther, 2006, 11, 857-867.